{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:05:51Z","timestamp":1781766351891,"version":"3.54.5"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T00:00:00Z","timestamp":1621468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007721","name":"Cure SMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To determine the safety and tolerability of nusinersen treatment in ambulatory adults with spinal muscular atrophy (SMA) and investigate the treatment effect on muscle strength, physical function, and motor unit physiology.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Individuals aged 18 years or older with genetically confirmed 5q SMA, three or more copies of the SMN2 gene, and the ability to ambulate 30 feet were enrolled. Safety outcomes included the number of adverse events and serious adverse events, clinically significant vital sign or laboratory parameter abnormalities. Outcome assessments occurred at baseline (prior to the first dose of nusinersen) and then 2, 6, 10, and 14 months post-treatment.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Six women, seven men (mean age: 37 \u00b1 11, range: 18\u201359 years) were included for analyses. The most common side effects were headache and back pain, but overall procedures and treatments were well-tolerated. No serious adverse events were reported. Maximal Voluntary Isometric Muscle Contraction Testing (MVICT) and 6-min walk test (6MWT) both showed overall stability with significant increases at 2, 6, and 10 months for the 6MWT. More consistent significant treatment effects were noted on the Hammersmith Functional Motor Scale Expanded, SMA-Functional Rating Scale, and forced vital capacity. Treatment resulted in progressively increased ulnar compound muscle action potential and average single motor unit potential amplitudes, but motor unit number estimation remained stable.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Nusinersen treatment is safe and well-tolerated in ambulatory adults with SMA. Treatment resulted in improved motor function and electrophysiological findings suggest that this improvement may be occurring <jats:italic>via<\/jats:italic> improved motor unit reinnervation capacity.<\/jats:p>","DOI":"10.3389\/fneur.2021.650535","type":"journal-article","created":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T05:28:49Z","timestamp":1621488529000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Safety, Tolerability, and Effect of Nusinersen Treatment in Ambulatory Adults With 5q-SMA"],"prefix":"10.3389","volume":"12","author":[{"given":"Bakri","family":"Elsheikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Severyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songzhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Linsenmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tellez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Heintzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Rajneesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. David","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ana.23995","article-title":"Spinal muscular atrophy: the development and implementation of potential treatments","volume":"74","author":"Arnold","year":"2013","journal-title":"Ann Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/ng0797-265","article-title":"Correlation between severity and SMN protein level in spinal muscular atrophy","volume":"16","author":"Lefebvre","year":"1997","journal-title":"Nat Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1093\/hmg\/8.7.1177","article-title":"A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2","volume":"8","author":"Monani","year":"1999","journal-title":"Hum Mol Genet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/hmg\/9.2.259","article-title":"An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN","volume":"9","author":"Lorson","year":"2000","journal-title":"Hum Mol Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11940-019-0568-z","article-title":"Current treatment options in neurology-SMA therapeutics","volume":"21","author":"Waldrop","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1080\/14737175.2017.1364159","volume":"17","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","article-title":"Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study","volume":"388","author":"Finkel","year":"2016","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","article-title":"Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3\u2014a prospective observational study","volume":"6","author":"Walter","year":"2019","journal-title":"J Neuromuscul Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","article-title":"Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience","volume":"61","author":"Veerapandiyan","year":"2020","journal-title":"Muscle Nerve"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1756286420907803","DOI":"10.1177\/1756286420907803","article-title":"Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen","volume":"13","author":"Jochmann","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"B14","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/JND-190453","article-title":"Prospective cohort study of nusinersen treatment in adults with spinal muscular atrophy","volume":"7","author":"Yeo","year":"2020","journal-title":"J Neuromuscul Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","article-title":"Nusinersen in adult patients with spinal muscular atrophy: observations from a single center","volume":"95","author":"Moshe-Lilie","year":"2020","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/mus.26756","article-title":"Outcome measures in a cohort of ambulatory adults with spinal muscular atrophy","volume":"61","author":"Elsheikh","year":"2020","journal-title":"Muscle Nerve."},{"key":"B19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","article-title":"Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c-4","volume":"25","author":"Wadman","year":"2018","journal-title":"Eur J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/mus.23904","article-title":"SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy","volume":"49","author":"Kissel","year":"2014","journal-title":"Muscle Nerve"},{"key":"B21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/ptj\/74.3.253","article-title":"Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group","volume":"74","author":"Personius","year":"1994","journal-title":"Phys Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","article-title":"Nusinersen in later-onset spinal muscular atrophy. Long term results from the phase 1\/2 studies","volume":"92","author":"Darras","year":"2019","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12883-017-0790-9","article-title":"Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy","volume":"17","author":"Pera","year":"2017","journal-title":"BMC Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS ONE"},{"key":"B25","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mus.25120","article-title":"Six-minute walk test is reliable and valid in spinal muscular atrophy","volume":"54","author":"Young","year":"2016","journal-title":"Muscle Nerve"},{"key":"B26","doi-asserted-by":"publisher","first-page":"E79","DOI":"10.1002\/mus.27042","article-title":"Possible recurrent aseptic meningitis associated with nusinersen therapy","volume":"62","author":"Moshe-Lilie","year":"2020","journal-title":"Muscle Nerve"},{"key":"B27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12883-017-0853-y","article-title":"A qualitative study of perceptions of meaningful change in spinal muscular atrophy","volume":"17","author":"McGraw","year":"2017","journal-title":"BMC Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.nbd.2015.12.014","article-title":"The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy","volume":"87","author":"Arnold","year":"2016","journal-title":"Neurobiol Dis"},{"key":"B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/acn3.23","article-title":"Electrophysiological biomarkers in spinal muscular atrophy: preclinical proof of concept","volume":"1","author":"Arnold","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ana.24332","article-title":"A large animal model of spinal muscular atrophy and correction of phenotype","volume":"77","author":"Duque","year":"2015","journal-title":"Ann Neurol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"650532","DOI":"10.3389\/fneur.2021.650532","article-title":"Safety, tolerability, and effect of Nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1136\/jnnp-2020-324254","article-title":"Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen","volume":"92","author":"Kariyawasam","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.650535\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T05:28:53Z","timestamp":1621488533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.650535\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":32,"alternative-id":["10.3389\/fneur.2021.650535"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.650535","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]},"article-number":"650535"}}